# US 2019/0031723 A1 · Truncated glycoprotein g of herpes simplex virus 2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0031723 A1
- Document ID: US20190031723A1
- Status: Published application
- Kind: A1
- Application number: 16/072,499
- Filed: 2017-01-31
- Published: 2019-01-31
- Earliest claimed: 2016-02-01
- Assignees: Simplexia AB
- Applicants: Simplexia AB
- Inventors: Jan-Åke LILJEQVIST
- Web page: https://patentgrep.com/patent/US20190031723A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- G01N 33/56994: {Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16071: Demonstrated in vivo effect
- G01N 2333/035: Herpes simplex virus I or II
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a protein comprising a truncated version of the HSV-2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or 95% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.

## Claims

### Claim 1

A protein comprising a truncated version of the HSV-2 protein mgG-2, said protein comprising:
(i) an extracellular region of mgG-2 (EX-mgG-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3;
(ii) a truncated transmembrane region of mgG-2 (t-TMR-mgG-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and
(iii) an intracellular region of mgG-2 (IC-mgG-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or at least 95%, sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.

### Claim 2 (depends on 1)

The protein according to claim 1, wherein the truncated transmembrane region (t-TMR-mgG-2) comprises from 2 to 10 amino acids (AA).

### Claim 3 (depends on 2)

The protein according to claim 2, wherein the truncated transmembrane region (t-TMR-mgG-2) comprises from 3 to 5 amino acids (AA).

### Claim 4 (depends on 1, 2, 3)

The protein according to any one of claims 1-3, wherein the truncated transmembrane region (t-TMR-mgG-2) has at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 9.

### Claim 5 (depends on 1, 2, 3)

The protein according to any one of claims 1-3, wherein the truncated transmembrane region (t-TMR-mgG-2) has at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 10.

### Claim 6 (depends on 1, 2, 3)

The protein according to any one of claims 1-3, wherein the truncated transmembrane region (t-TMR-mgG-2) has at least 80% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 11.

### Claim 7 (depends on 1, 2, 3)

The protein according to any one of claims 1-3, wherein the truncated transmembrane region (t-TMR-mgG-2) has at least 80% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 12.

### Claim 8 (depends on 1, 2, 3)

The protein according to any one of claims 1-3, wherein the truncated transmembrane region (t-TMR-mgG-2) has the amino acid sequence of SEQ ID NO: 7.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The protein according to any one of claims 1-8, wherein the extracellular region of mgG-2 (EX-mgG-2) is truncated.

### Claim 10 (depends on 9)

The protein according to claim 9, wherein the truncated extracellular region of mgG-2 (EX-mgG-2) shares 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3.

### Claim 11 (depends on 9, 10)

The protein according to claim 9 or 10, wherein the truncated extracellular region of mgG-2 (EX-mgG-2) comprises at least 290, 295, or 300 amino acids.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The protein according to any one of claims 1-11, wherein the intracellular region of mgG-2 (IC-mgG-2) is truncated.

### Claim 13 (depends on 12)

The protein according to claim 12, wherein the truncated intracellular region of mgG-2 (IC-mgG-2) comprises 18, 20, 22, 24 or 26 amino acids.

### Claim 14 (depends on 12, 13)

The protein according to claim 12 or claim 13, wherein the truncated intracellular region of mgG-2 (IC-mgG-2) shares at least 90%, or at least 95%, sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.

### Claim 15 (depends on 1, 2, 3)

The protein according to any one of claim 1-3, wherein said protein comprises:
(i) amino acids 345-649 of the extracellular region (SEQ ID NO: 3) of mgG-2;
(ii) amino acids 667-670 of the TMR (SEQ ID NO: 7) of mgG-2; and
(iii) amino acids 671-698 of the intracellular region (SEQ ID NO: 8) of mgG-2.

### Claim 16 (depends on 15)

The protein EXCT4-mgG-2 according to claim 15, having an amino acid sequence as defined in SEQ ID NO:5, or an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 5.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition comprising a protein as defined in any one of claims 1 to 16, together with one or more components selected from the group consisting of adjuvants, stabilizers, buffers, surfactants, salts and preservatives.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A protein as defined in any one of claims 1-16, for use in therapy.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A protein as defined in any one of claims 1-16 for use in the prevention and/or treatment of a disorder related to herpes simplex virus 2 (HSV-2).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An HSV-2 vaccine comprising a protein as defined in any one of claims 1 to 16.

### Claim 21 (depends on 20)

The HSV-2 vaccine according to claim 20, wherein the protein is EXCT4-mgG-2, having an amino acid sequence as defined in SEQ ID NO:5.

### Claim 22 (depends on 20, 21)

The HSV-2 vaccine according to claim 20 or 21, wherein the effective dose of the protein is 0.5-1000 μg.

### Claim 23 (depends on 22)

The HSV-2 vaccine according to claim 22, wherein the effective dose of the protein is 20-200 μg.

### Claim 24 (depends on 23)

The HSV-2 vaccine according to claim 23, wherein the effective dose of the protein is 50-100 μg.

### Claim 25

The protein, pharmaceutical composition or HSV-2 vaccine as defined in any one of the preceding claims, for use in therapy in combination with a second HSV-2 glycoprotein.

### Claim 26 (depends on 25)

The protein, pharmaceutical composition or HSV-2 vaccine and second HSV-2 glycoprotein for use according to claim 25, wherein the second HSV-2 glycoprotein is selected from any one of gB, gC, gD, gE, gH, gI, gK, gL, and gM, and fragments thereof.

### Claim 27 (depends on 25, 26)

The protein, pharmaceutical composition or HSV-2 vaccine and second HSV-2 glycoprotein for use according to claim 25 or 26, wherein said combination further includes an HSV non-glycoprotein.

### Claim 28 (depends on 27)

The protein, pharmaceutical composition or HSV-2 vaccine, second HSV-2 glycoprotein and HSV non-glycoprotein for use according to claim 27, wherein the HSV non-glycoprotein is selected from any one of UL11, UL14, UL16, UL17, UL21, UL36, UL37, UL41, UL46, UL48, UL49, US6, US7, USB, US11, VP13/14, VP16, VP22, VPS, VP19c, VP21, VP23, VP24, and VP26.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use of a protein as defined in any one of claims 1-16 for the manufacture of a medicament for use in the prevention and/or treatment of HSV-2 or a disorder related to HSV-2.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method for the treatment and/or prevention of an HSV-2 related disease and/or infection, whereby a protein as defined in any one of claims 1-16, is administered to a subject in need of such prevention and/or treatment.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An isolated nucleic acid encoding a protein as defined in any one of claims 1-16

### Claim 32 (depends on 31)

A vector comprising a nucleic acid as defined in claim 31.

### Claim 33 (depends on 32)

A cell comprising the vector of claim 32.

### Claim 34 (depends on 32)

A method for producing an HSV-2 vaccine, wherein a host cell is transfected with a vector as defined in claim 32.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the host cell is selected from the group consisting of CHO, HEK293, CAP and PER.C6 cells.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use of a protein according to any one of claims 1-16 as an antigen in the detection of antibodies against HSV-2.

### Claim 37 (depends on 36)

The use of claim 36, wherein said protein is used a diagnostic antigen to detect an HSV-2 infection.
